JP6122639B2 - インテグラーゼ阻害剤を含有する固形医薬組成物 - Google Patents

インテグラーゼ阻害剤を含有する固形医薬組成物 Download PDF

Info

Publication number: JP6122639B2
Authority: JP; Japan
Prior art keywords: amounts ranging; compressed tablet; raltegravir; iii; superdisintegrant
Prior art date: 2009-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2012535360A

Other languages

English (en)

Japanese (ja)

Other versions

JP2013508395A (ja

Inventor

マージヨール，マジード

リー，フオン

マー，ドウチユヨン

ソツテイビラツト，スツテイルグ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck and Co Inc

Original Assignee

Merck and Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-26

Filing date

2010-10-21

Publication date

2017-04-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6122639(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-21 Application filed by Merck and Co Inc filed Critical Merck and Co Inc

2013-03-07 Publication of JP2013508395A publication Critical patent/JP2013508395A/ja

2017-04-26 Application granted granted Critical

2017-04-26 Publication of JP6122639B2 publication Critical patent/JP6122639B2/ja

Status Active legal-status Critical Current

2030-10-21 Anticipated expiration legal-status Critical

Links

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2012535360A 2009-10-26 2010-10-21 インテグラーゼ阻害剤を含有する固形医薬組成物 Active JP6122639B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25486909P	2009-10-26	2009-10-26
US61/254,869		2009-10-26
PCT/US2010/053507 WO2011053504A1 (en)	2009-10-26	2010-10-21	Solid pharmaceutical compositions containing an integrase inhibitor

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2015188605A Division JP2016034962A (ja)	2009-10-26	2015-09-25	インテグラーゼ阻害剤を含有する固形医薬組成物

Publications (2)

Publication Number	Publication Date
JP2013508395A JP2013508395A (ja)	2013-03-07
JP6122639B2 true JP6122639B2 (ja)	2017-04-26

Family

ID=43922462

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2012535360A Active JP6122639B2 (ja)	2009-10-26	2010-10-21	インテグラーゼ阻害剤を含有する固形医薬組成物
JP2015188605A Pending JP2016034962A (ja)	2009-10-26	2015-09-25	インテグラーゼ阻害剤を含有する固形医薬組成物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2015188605A Pending JP2016034962A (ja)	2009-10-26	2015-09-25	インテグラーゼ阻害剤を含有する固形医薬組成物

Country Status (26)

Country	Link
US (2)	US9649311B2 (2)
EP (2)	EP2493312B1 (2)
JP (2)	JP6122639B2 (2)
KR (1)	KR101835893B1 (2)
CN (2)	CN106074411A (2)
AU (1)	AU2010313571B2 (2)
BR (1)	BR112012009857A8 (2)
CA (1)	CA2777937C (2)
CO (1)	CO6531485A2 (2)
CY (1)	CY1124914T1 (2)
DK (1)	DK2493312T3 (2)
ES (1)	ES2898348T3 (2)
HR (1)	HRP20211826T1 (2)
HU (1)	HUE057248T2 (2)
IL (1)	IL219369A (2)
IN (1)	IN2012DN03377A (2)
LT (1)	LT2493312T (2)
MX (1)	MX345227B (2)
MY (1)	MY162494A (2)
PL (1)	PL2493312T3 (2)
PT (1)	PT2493312T (2)
RS (1)	RS62600B1 (2)
RU (1)	RU2602865C2 (2)
SI (1)	SI2493312T1 (2)
WO (1)	WO2011053504A1 (2)
ZA (1)	ZA201203012B (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9649311B2 (en)	2009-10-26	2017-05-16	Merck Sharp & Dohme Corp.	Solid pharmaceutical compositions containing an integrase inhibitor
AU2012245524A1 (en) *	2011-04-22	2013-10-24	Merck Sharp & Dohme Corp.	Taste-masked formulations of raltegravir
US20150166520A1 (en) *	2012-07-20	2015-06-18	Merck Sharp & Dohme Corp.	Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
WO2014064711A2 (en) *	2012-10-22	2014-05-01	Hetero Research Foundation	Methods of administering raltegravir and raltegravir compositions
AU2013336491B2 (en)	2012-10-23	2018-08-02	Cipla Limited	Pharmaceutical antiretroviral composition
WO2015006177A1 (en) *	2013-07-11	2015-01-15	Merck Sharp & Dohme Corp.	Formulations for cathepsin k inhibitors with vitamin d
CN105237526B (zh) *	2014-06-20	2018-01-23	朱靖华	一种抗艾滋病毒药物及其制备方法
JP7023054B2 (ja) *	2017-04-05	2022-02-21	東和薬品株式会社	レベチラセタム含有医薬組成物及びその製造方法
EP3740209A1 (en) *	2018-01-19	2020-11-25	Gilead Sciences, Inc.	Metabolites of bictegravir
EP3801532B1 (en) *	2018-06-06	2025-11-05	Merck Sharp & Dohme LLC	Formulations of raltegravir
RU2688235C1 (ru) *	2018-06-19	2019-05-21	Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет"	Фармацевтическая противодиабетическая композиция на основе замещенного тиофенкарбоксилата и способ её получения
JP7603000B2 (ja)	2018-08-31	2024-12-19	オプコアイルランドグローバルホールディングスリミテッド	ビタミンｄ小児用剤形、製造方法および使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9109862D0 (en)	1991-05-08	1991-07-03	Beecham Lab Sa	Pharmaceutical formulations
US6087383A (en)	1998-01-20	2000-07-11	Bristol-Myers Squibb Company	Bisulfate salt of HIV protease inhibitor
GB9922963D0 (en)	1999-09-28	1999-12-01	Pfizer Ltd	Polymorphic salt
FR2795962B1 (fr) *	1999-07-08	2003-05-09	Prographarm Laboratoires	Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6642237B1 (en)	1999-11-24	2003-11-04	Merck & Co., Inc.	Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
PL360944A1 (en)	2000-10-12	2004-09-20	Merck & Co, Inc.	Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
ATE355064T1 (de)	2001-10-26	2006-03-15	Angeletti P Ist Richerche Bio	Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
IL161337A0 (en)	2001-10-26	2004-09-27	Angeletti P Ist Richerche Bio	N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
AU2003220186A1 (en)	2002-04-10	2003-10-27	Merck And Co., Inc.	Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
NZ540729A (en)	2002-12-27	2008-03-28	Angeletti P Ist Richerche Bio	Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
ATE500819T1 (de)	2003-12-31	2011-03-15	Bend Res Inc	Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
EP1904067B2 (en)	2004-12-03	2017-10-11	Merck Sharp & Dohme Corp.	Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
BRPI0518741A2 (pt)	2004-12-03	2008-12-02	Merck & Co Inc	uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
EP1819323B2 (en) *	2004-12-03	2023-03-22	Merck Sharp & Dohme Corp.	Pharmaceutical composition containing an anti-nucleating agent
UA87884C2 (uk)	2004-12-03	2009-08-25	Мерк Энд Ко., Инк.	Безводна кристалічна калієва сіль інгібітора віл-інтегрази
WO2007087188A2 (en)	2006-01-20	2007-08-02	Merck & Co., Inc.	Taste-masked tablets and granules
CA2563690C (en) *	2006-10-12	2014-10-07	Pharmascience Inc.	Pharmaceutical compositions comprising intra- and extra- granular fractions
DE602008005316D1 (de)	2007-06-22	2011-04-14	Bristol Myers Squibb Co	Tablettierte atazanavirhaltige zusammensetzungen
US7687509B2 (en) *	2007-07-09	2010-03-30	Concert Pharmaceuticals Inc.	Pyrimidinecarboxamide derivatives
US8372431B2 (en) *	2007-10-26	2013-02-12	Bial-Portela & C.A., S.A.	Pharmaceutical composition comprising licarbazepine acetate
US9649311B2 (en) *	2009-10-26	2017-05-16	Merck Sharp & Dohme Corp.	Solid pharmaceutical compositions containing an integrase inhibitor

2010
- 2010-10-21 US US13/503,939 patent/US9649311B2/en active Active
- 2010-10-21 DK DK10827338.4T patent/DK2493312T3/da active
- 2010-10-21 CN CN201610500807.0A patent/CN106074411A/zh active Pending
- 2010-10-21 RU RU2012121857/15A patent/RU2602865C2/ru active
- 2010-10-21 CA CA2777937A patent/CA2777937C/en active Active
- 2010-10-21 KR KR1020127013561A patent/KR101835893B1/ko active Active
- 2010-10-21 EP EP10827338.4A patent/EP2493312B1/en active Active
- 2010-10-21 PL PL10827338T patent/PL2493312T3/pl unknown
- 2010-10-21 PT PT108273384T patent/PT2493312T/pt unknown
- 2010-10-21 JP JP2012535360A patent/JP6122639B2/ja active Active
- 2010-10-21 BR BR112012009857A patent/BR112012009857A8/pt not_active Application Discontinuation
- 2010-10-21 WO PCT/US2010/053507 patent/WO2011053504A1/en not_active Ceased
- 2010-10-21 LT LTEPPCT/US2010/053507T patent/LT2493312T/lt unknown
- 2010-10-21 ES ES10827338T patent/ES2898348T3/es active Active
- 2010-10-21 MY MYPI2012001823A patent/MY162494A/en unknown
- 2010-10-21 CN CN2010800593740A patent/CN102655752A/zh active Pending
- 2010-10-21 EP EP21202505.0A patent/EP3970702A1/en active Pending
- 2010-10-21 HR HRP20211826TT patent/HRP20211826T1/hr unknown
- 2010-10-21 RS RS20211443A patent/RS62600B1/sr unknown
- 2010-10-21 SI SI201032094T patent/SI2493312T1/sl unknown
- 2010-10-21 AU AU2010313571A patent/AU2010313571B2/en active Active
- 2010-10-21 MX MX2012004903A patent/MX345227B/es active IP Right Grant
- 2010-10-21 IN IN3377DEN2012 patent/IN2012DN03377A/en unknown
- 2010-10-21 HU HUE10827338A patent/HUE057248T2/hu unknown
2012
- 2012-04-23 IL IL219369A patent/IL219369A/en active IP Right Grant
- 2012-04-24 ZA ZA2012/03012A patent/ZA201203012B/en unknown
- 2012-04-26 CO CO12068959A patent/CO6531485A2/es unknown
2015
- 2015-09-25 JP JP2015188605A patent/JP2016034962A/ja active Pending
2017
- 2017-04-10 US US15/483,030 patent/US10772888B2/en active Active
2021
- 2021-12-14 CY CY20211101099T patent/CY1124914T1/el unknown

Also Published As

Publication number	Publication date
BR112012009857A2 (pt)	2015-09-29
IL219369A (en)	2017-06-29
EP2493312A1 (en)	2012-09-05
CN106074411A (zh)	2016-11-09
ZA201203012B (en)	2012-12-27
EP3970702A1 (en)	2022-03-23
AU2010313571A1 (en)	2012-06-07
LT2493312T (lt)	2022-01-10
KR101835893B1 (ko)	2018-04-19
CO6531485A2 (es)	2012-09-28
SI2493312T1 (sl)	2021-12-31
KR20120102063A (ko)	2012-09-17
JP2016034962A (ja)	2016-03-17
US10772888B2 (en)	2020-09-15
DK2493312T3 (da)	2021-12-13
EP2493312B1 (en)	2021-10-20
WO2011053504A1 (en)	2011-05-05
CY1124914T1 (el)	2023-01-05
MX2012004903A (es)	2012-06-14
US9649311B2 (en)	2017-05-16
CN102655752A (zh)	2012-09-05
US20120213851A1 (en)	2012-08-23
MY162494A (en)	2017-06-15
RU2602865C2 (ru)	2016-11-20
RU2012121857A (ru)	2013-12-10
BR112012009857A8 (pt)	2023-04-11
IL219369A0 (en)	2012-06-28
CA2777937A1 (en)	2011-05-05
ES2898348T3 (es)	2022-03-07
IN2012DN03377A (2)	2015-10-23
AU2010313571B2 (en)	2014-07-31
HUE057248T2 (hu)	2022-04-28
MX345227B (es)	2017-01-20
US20170231993A1 (en)	2017-08-17
JP2013508395A (ja)	2013-03-07
PL2493312T3 (pl)	2022-01-03
EP2493312A4 (en)	2013-07-10
PT2493312T (pt)	2021-11-25
RS62600B1 (sr)	2021-12-31
CA2777937C (en)	2017-08-29
HRP20211826T1 (hr)	2022-03-04

Legal Events

Date	Code	Title	Description
2013-05-25	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130524
2014-05-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140527
2014-08-22	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140821
2014-08-29	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140828
2014-11-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141126
2015-05-27	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150526
2015-09-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150928
2015-11-25	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151124
2016-01-18	A912	Re-examination (zenchi) completed and case transferred to appeal board	Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20160115
2017-01-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170124
2017-04-06	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170403
2017-04-07	R150	Certificate of patent or registration of utility model	Ref document number: 6122639 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2019-05-08	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2020-03-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-03-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-03-25	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-10-06	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313111
2022-11-09	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2023-03-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-06-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-04-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2026-04-09	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6122639B2 (ja)	2017-04-26	インテグラーゼ阻害剤を含有する固形医薬組成物
US6555133B2 (en)	2003-04-29	Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
RU2456989C2 (ru)	2012-07-27	Твердые лекарственные формы, содержащие тадалафил
AU2012250862B2 (en)	2015-07-09	Rapid dissolve tablet compositions for vaginal administration
EP2729130B1 (en)	2017-09-06	Darunavir combination formulations
JP5417662B2 (ja)	2014-02-19	ネビラピンの徐放性製剤
TR201901792T4 (tr)	2019-03-21	Yeni (trimetoksifenilamino)pirimidinil formülasyonları.
RU2679448C2 (ru)	2019-02-11	Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением
HK40069975A (en)	2022-10-21	Solid pharmaceutical compositions containing an integrase inhibitor
WO2017029225A1 (en)	2017-02-23	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
JP5638527B2 (ja)	2014-12-10	Ｈｉｖ結合阻害剤の最適な送達のための安定な医薬組成物
RU2543322C1 (ru)	2015-02-27	Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
CN104784133A (zh)	2015-07-22	一种齐多夫定的片剂及其制备方法
HK1145806B (en)	2013-08-02	Extended release formulation of nevirapine